The Food and Drug Administration has formally approved Pfizer's COVID-19 vaccine. The widely anticipated decision replaces the emergency use authorization granted by the agency last December.
The vaccine,
developed by Pfizer and its partner BioNTech, is the first COVID-19 vaccine to
be subject to a full review by the U.S. regulator and to get an approval that
puts the vaccine on par with other marketed vaccines.
The full
approval could make it easier for employers, the military and universities to
mandate vaccination and may reassure some people who are hesitant about the
vaccine.
"While
this and other vaccines have met the FDA's rigorous, scientific standards for
emergency use authorization, as the first FDA-approved COVID-19 vaccine, the
public can be very confident that this vaccine meets the high standards for
safety, effectiveness, and manufacturing quality the FDA requires of an
approved product," acting FDA Commissioner Janet Woodcock said in statement
.
President
Biden seized on the announcement in remarks to the nation on Monday afternoon
to press for more people to get vaccinated as soon as possible.
"Let me
say this loudly and clearly: If you're one of the
millions of Americans who said that they will not get the shot until it has
full and final approval of the FDA, it has now happened," he said.
"The moment you've been waiting for is here. It's time for you to go get
your vaccination. Get it today."
The
president also encouraged businesses to "step up their vaccine
requirements."
Approval Could Lead To More Vaccinations
Advertisement
"While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated," Woodcock said. "Today's milestone puts us one step closer to altering the course of this pandemic in the U.S."
The FDA's full approval applies to people 16 and older. Those ages 12 through 15 can still receive the vaccine under the existing emergency use authorization.
There Is No Timeline
For Children Under 12
That
authorization does not extend to children under the age of 12. FDA officials
have acknowledged the interest in vaccination for children in that age group
but were unable Monday to provide a timeline for a decision on use of the
vaccine for those under 12.
As part of the approval process, the vaccine also got a brand name: Comirnaty. The FDA says that's pronounced "koe-mir'-na-tee."
As of Sunday, 73% of adult in the US have had at least one does of the Pfizer, Moderna or Johnson & Johnson vaccines. Pfizer's vaccine is most commonly administered, accounting for about 56% of the doses administered overall, according to data from the Centers for Disease Control and Prevention.
Moderna's COVID-19 vaccine remains under the FDA's review, but its approval is expected to follow in the near future.